AG˹ٷ

STOCK TITAN

InnovAge Announces Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2025

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags

InnovAge (NASDAQ:INNV), a leader in Program of All-inclusive Care for the Elderly (PACE), reported its fiscal Q4 and full year 2025 results. Total revenue reached $853.7 million, up 11.8% year-over-year, while net loss widened to $35.3 million ($0.22 per share) from $23.2 million in 2024.

The company demonstrated operational growth with census increasing to 7,740 participants from 7,020 in 2024. Adjusted EBITDA improved to $34.5 million with a margin of 4.0%, up from $16.5 million and 2.2% in 2024. For fiscal 2026, InnovAge projects revenue between $900-950 million and expects census to reach 7,900-8,100 participants.

InnovAge (NASDAQ:INNV), leader nel Program of All-inclusive Care for the Elderly (PACE), ha comunicato i risultati del quarto trimestre fiscale e dell'intero esercizio 2025. I ricavi totali hanno raggiunto $853.7 million, in crescita dell'11,8% su base annua, mentre la perdita netta si è ampliata a $35.3 million (pari a $0,22 per azione) rispetto a $23.2 million nel 2024.

L'azienda ha mostrato crescita operativa con il censimento che è salito a 7,740 participants rispetto a 7,020 nel 2024. L'Adjusted EBITDA è migliorato a $34.5 million con un margine del 4,0%, rispetto a $16.5 million e 2,2% nel 2024. Per l'esercizio 2026 InnovAge prevede ricavi tra $900-950 million e si aspetta un censimento compreso tra 7,900 e 8,100 participants.

InnovAge (NASDAQ:INNV), líder en el Programa de Atención Integral para Personas Mayores (PACE), informó sus resultados del cuarto trimestre fiscal y del año fiscal 2025. Los ingresos totales alcanzaron $853.7 million, un aumento del 11.8% interanual, mientras que la pérdida neta se amplió a $35.3 million ($0.22 por acción) desde $23.2 million en 2024.

La compañía mostró crecimiento operativo con el censo que aumentó a 7,740 participants desde 7,020 en 2024. El EBITDA ajustado mejoró a $34.5 million con un margen del 4.0%, frente a $16.5 million y 2.2% en 2024. Para el año fiscal 2026, InnovAge proyecta ingresos entre $900-950 million y espera que el censo llegue a 7,900-8,100 participants.

InnovAge (NASDAQ:INNV), 노인 전면통합케� 프로그램(PACE) 분야� 선두 기업, 2025 회계연도 4분기 � 연간 실적� 발표했습니다. 총매출은 $853.7 million� 전년 대� 11.8% 증가했으�, 순손실은 $35.3 million($0.22 주당)으로 2024년의 $23.2 million에서 확대되었습니�.

운영 측면에서� 등록 인원� 2024� 7,020명에� 7,740 participants� 늘어� 성장세를 보였습니�. 조정 EBITDA� $34.5 million으로 개선되어 마진은 4.0%� 기록했으�, 2024년의 $16.5 million·2.2%에서 향상되었습니�. 2026 회계연도� InnovAge� 매출� $900-950 million 범위� 예상하고 등록 인원은 7,900~8,100 participants� 이를 것으� 전망합니�.

InnovAge (NASDAQ:INNV), leader du programme PACE (Program of All-inclusive Care for the Elderly), a publié ses résultats du quatrième trimestre fiscal et de l'exercice 2025. Le chiffre d'affaires total s'est élevé à $853.7 million, en hausse de 11,8% sur un an, tandis que la perte nette s'est creusée à $35.3 million (0,22 $ par action) contre 23,2 $ en 2024.

L'entreprise a montré une croissance opérationnelle avec un effectif passant à 7,740 participants contre 7,020 en 2024. L'EBITDA ajusté s'est amélioré à $34.5 million avec une marge de 4,0%, contre 16,5 $ et 2,2% en 2024. Pour l'exercice 2026, InnovAge prévoit un chiffre d'affaires compris entre $900-950 million et s'attend à un effectif de 7,900�8,100 participants.

InnovAge (NASDAQ:INNV), ein führendes Unternehmen im Programm "Program of All-inclusive Care for the Elderly" (PACE), veröffentlichte seine Ergebnisse für das vierte Fiskalquartal und das Gesamtjahr 2025. Der Gesamtumsatz belief sich auf $853.7 million, ein Anstieg von 11,8% gegenüber dem Vorjahr, während der Nettoverlust auf $35.3 million ($0,22 je Aktie) gegenüber $23.2 million im Jahr 2024 anwuchs.

Das Unternehmen verzeichnete operatives Wachstum: die Teilnehmerzahl stieg auf 7,740 participants gegenüber 7,020 im Jahr 2024. Das bereinigte EBITDA verbesserte sich auf $34.5 million mit einer Marge von 4,0%, nach $16.5 million und 2,2% in 2024. Für das Fiskaljahr 2026 prognostiziert InnovAge einen Umsatz von $900-950 million und erwartet eine Teilnehmerzahl von 7,900�8,100 participants.

Positive
  • Revenue growth of 11.8% year-over-year to $853.7 million
  • Participant census increased 10.3% to 7,740
  • Adjusted EBITDA doubled to $34.5 million from $16.5 million
  • Center-level Contribution Margin improved 16.3% to $153.6 million
  • Strong FY2026 guidance projecting revenue up to $950 million
Negative
  • Net loss widened 52% to $35.3 million
  • Net loss margin deteriorated to 4.1% from 3.0%
  • Loss per share increased to $0.22 from $0.16
  • Loss Before Income Taxes increased 56% to $34.0 million

Insights

InnovAge showed 11.8% revenue growth but increased losses, while improving non-GAAP metrics and providing optimistic 2026 guidance.

InnovAge reported $853.7 million in total revenue for fiscal 2025, an 11.8% increase from the previous year, driven by census growth to approximately 7,740 participants (up from 7,020). However, the company's financial performance shows concerning trends in profitability. Net loss widened to $35.3 million, a 52% increase from fiscal 2024's $23.2 million loss, with net loss margin deteriorating to 4.1% from 3.0%.

Despite the increased losses, the company improved its non-GAAP metrics. Center-level Contribution Margin grew 16.3% to $153.6 million, representing 18% of revenue (up 0.7 percentage points). Adjusted EBITDA more than doubled to $34.5 million from $16.5 million, with margin expanding to 4.0% from 2.2%. This divergence between GAAP and non-GAAP results suggests the company is making operational improvements at the center level while dealing with higher corporate expenses or non-recurring costs.

For fiscal 2026, management projects continued growth with census expanding to 7,900-8,100 participants, revenue reaching $900-950 million (implying 5.4-11.3% growth), and Adjusted EBITDA of $56-65 million (a significant 62-89% increase). This guidance suggests management expects operational efficiencies to continue improving significantly.

InnovAge's business model focuses on PACE (Program of All-inclusive Care for the Elderly), serving frail, predominantly dual-eligible seniors. The company operates 20 centers across six states. The fundamental challenge remains converting its growing revenue and improving center-level operations into bottom-line profitability. The significant projected improvement in Adjusted EBITDA for 2026 will be a critical metric to watch as the company attempts to narrow its GAAP losses while continuing to expand.

DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge� or the “Company�) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal fourth quarter and full year ended June 30, 2025.

“Fiscal 2025 was a strong year. The combination of responsible growth, financial discipline, clinical performance, and compliance execution is what gives us confidence in the durability of our progress.� said Patrick Blair, CEO. “We expect Fiscal 2026 to continue that momentum.�

Financial Results

Three Months EndedYear Ended
June 30,
2025
June 30,
2024
June 30,
2025
June 30,
2024
in thousands, except percentages and per share amounts
Total revenues$221,417199,401$853,699$763,855
Loss Before Income Taxes(4,202)(946)(34,027)(21,819)
Net Loss(5,009)(2,254)(35,343)(23,221)
Net Loss margin(2.3)%(1.1)%(4.1)%(3.0)%
Net Loss Attributable to InnovAge Holding Corp.$(785)$(1,700)$(30,313)$(21,338)
Net Loss per share - basic and diluted(0.01)(0.01)(0.22)(0.16)
Center-level Contribution Margin(1)$41,287$36,578$153,639$132,064
Adjusted EBITDA(1)11,3265,23734,46216,474
Adjusted EBITDA marginicles/ebitda-vs-operating-income" title="Read: EBITDA vs Operating Income: Key Differences Every Investor Should Know" class="article-link" rel="noopener">EBITDA margin(1)5.1%2.6%4.0%2.2%

Fiscal Year 2025 Financial Performance

  • Total revenue of$853.7 million, increased approximately 11.8% compared to $763.9 million in 2024
  • Loss Before Income Taxes of $34.0 million, increased by 56.0% compared to a Loss Before Income Taxes of $21.8 million in 2024
  • Loss Before Income Taxes as a percent of revenue of 4.0% increased 1.1 percentage points compared to Loss Before Income Tax as a percent of revenue of 2.9% in 2024
  • Net loss of $35.3 million increased 52%, compared to a net loss of $23.2 million in 2024
  • Net loss margin of 4.1%, increased 1.1 percentage points compared to a net loss margin of 3.0% in 2024
  • Net loss attributable to InnovAge Holding Corp. of $30.3 million, or a loss of $0.22 per share, compared to a net loss of $21.3 million, or $0.16 per share in 2024
  • Center-level Contribution Margin(1) of $153.6 million, increased 16.3% compared to $132.1 million in 2024
  • Center-level Contribution Margin(1)as a percent of revenue of 18.0%, increased 0.7 percentage points compared to 17.3% in 2024
  • Adjusted EBITDA(1)of $34.5 million, an increase of $18.0 million compared to $16.5 million in 2024
  • Adjusted EBITDA(1)margin of 4.0%, an increase of 1.9 percentage points compared to 2.2% in 2024
  • Census of approximately 7,740 participants compared to 7,020 participants in 2024

(1) Center-level Contribution Margin, Center-level Contribution Margin as a percent of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For more details and for a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the periods indicated, see “NoteRegarding Use of Non-GAAP Financial Measures� and “Reconciliation of GAAP and Non-GAAP Measures.�

Full Fiscal Year 2026 Financial Guidance

Based on information as of today, September 9, 2025, InnovAge is issuing the following financial guidance.

LowHigh
dollars in millions
Census7,9008,100
Total Member Months(1)91,60094,400
Total revenues$900$950
Adjusted EBITDA(2)5665

Expected results and estimates may be impacted by factors outside the Company’s control, and actual results may be materially different from this guidance. See “Forward-Looking Statements - Safe Harbor� included herein.

(1) We define Total Member Months as the total number of participants multiplied by the number of months within a year in which each participant was enrolled in our program. Management believes this is a useful metric as it more precisely tracks the number of participants the Company serves throughout the year.

(2)Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures� and “Reconciliation of GAAP and Non-GAAP Measures� for a definition of historical Adjusted EBITDA and a reconciliation to net loss, the most closely comparable GAAP measure. The Company is unable to provide guidance for net loss or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.

Conference Call

The Company will host a conference call this afternoon at 5:00 p.m. Eastern Time. A live audio webcast of the call will be available on the Company’s website, . A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link (), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.

About InnovAge

InnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies� participants, their families, providers and government payors � “win.� As of June 30, 2025, InnovAge served approximately 7,740 participants across 20 centers in six states. .

Investor Contact:

Ryan Kubota
[email protected]

Media Contact:

Lara Hazenfield
[email protected]

Forward-Looking Statements- Safe Harbor
This press release may contain “forward-looking statements� within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,� “estimate,� “expect,� “project,� “plan,� “intend,� “believe,� “may,� “will,� “should,� “can have,� “likely� and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements include, among others, statements we may make regarding quarterly or annual guidance; financial outlook, including future revenues and future earnings; the viability of our growth strategy including our ability or expectations to increase the number of participants we serve, build and/or open de novo centers, or to identify and execute tuck-in acquisitions, joint ventures and strategic partnerships; the expected impact of government policies and the macroeconomic environment; our ability to control costs, mitigate the effects of elevated expenses or reduced healthcare budgets, expand our payer capabilities, implement clinical value and operational value initiatives and strengthen enterprise functions; results of periodic inspections, reviews and audits, legal proceedings and government investigations and actions; relationships and discussions with regulatory agencies; our ability to effectively implement Company-wide transformation initiatives; reimbursement and regulatory developments; market developments; new pharmacy services; and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on currently available information and our current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control and may cause our actual results and financial condition to differ materially. Important factors that could cause our actual results and financial condition to differ materially include, among others, the following: (i) the viability of our growth strategy, including our ability to find suitable geographies for new centers and to attract new participant and retain existing participants in new and existing centers and our ability to obtain licenses to open such centers; (ii) our ability to identify, successfully complete and integrate acquisitions, joint ventures another strategic partnerships; (iii) the impact on our business from ongoing macroeconomic related challenges, including labor shortages, labor competition, inflation, tariffs and trade disputes; (iv) inspections, reviews, audits and investigations under the federal and state government programs, including our ability to sufficiently cure any deficiencies identified; (v) legal proceedings, enforcement actions and litigation and disputes, which are costly to defend; (vi) under our PACE contracts, we assume all of the risk that the cost of providing services will exceed our compensation; (vii) the dependence of our revenues upon a limited number of government payors, including the risk of sudden loss of any of our government contracts; (viii) the impact of state and federal efforts to reduce healthcare spending, including recent legislation reducing the budget that funds Medicaid; (ix) the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants, subjecting us to repayment obligations or penalties; (x) and our ability to comply with the continued listing requirements of Nasdaq.

Forward-looking statements are based only on information currently available to us and speaks only as of the date on which it is made. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. We advise you to not place undue reliance on forward-looking statements and to review our risk factors and other disclosures included in the reports we file or furnish with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

NoteRegarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP�), the Company is also reporting Center-level Contribution Margin, Center-level Contribution Margin as a percent of revenue, Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. These non-GAAP measures are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) before income taxes, net income (loss) before income taxes margin, net income (loss) and net income (loss) margin, as applicable, as determined by GAAP. We believe that these non-GAAP measures are appropriate measures of operating performance because the metrics eliminate the impact of certain expenses that, in the case of Adjusted EBITDA, do not relate to our ongoing business performance, allowing us to more effectively evaluate our core operating performance and trends from period to period. Our definitions and calculations of non-GAAP measures may vary and not be comparable to similarly titled measures reported by other companies. We believe that these non-GAAP measures help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other comparable GAAP financial measures.

The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments and allocating resources, predominantly in the annual budget and forecasting process. For the purpose of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expense or corporate, general and administrative expenses across our centers. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs.

We define Adjusted EBITDA as net loss adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, litigation costs and settlement, M&A diligence, transaction and integration, business optimization, electronic medical record (EMR) implementation, gain (loss) on cost and equity method investments, asset impairments and loss on sale of assets. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue.

Schedule 1

InnovAge
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT NUMBER OF SHARES)

June 30,
2025
June 30,
2024
Assets
Current Assets
Cash and cash equivalents$64,129$56,946
Short-term investments41,77545,833
Restricted cash1114
Accounts receivable, net of allowance ($� � June30, 2025 and $6,729 � June30, 2024)36,37348,106
Prepaid expenses24,47218,919
Income tax receivable3,3103,324
Assets held for sale6,038
Total current assets176,108173,142
Noncurrent Assets
Property and equipment, net168,044193,022
Operating lease assets26,90128,416
Investments2,645
Deposits and other9,8755,949
Goodwill142,046139,949
Other intangible assets, net3,8774,538
Total noncurrent assets350,743374,519
Total assets$526,851$547,661
Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable and accrued expenses$76,750$55,459
Reported and estimated claims58,97155,404
Due to Medicaid and Medicare14,38215,197
Current portion of long-term debt2,2503,795
Current portion of finance lease obligations5,2344,599
Current portion of operating lease obligations4,6824,145
Liabilities held for sale2,538
Total current liabilities164,807138,599
Noncurrent Liabilities
Deferred tax liability, net8,7617,460
Finance lease obligations7,53512,743
Operating lease obligations23,91826,275
Other noncurrent liabilities1,4581,298
Long-term debt, net of debt issuance costs57,46461,478
Total liabilities263,943247,853
Commitments and Contingencies (See Note 9)
Redeemable Noncontrolling Interest (See Note 4)25,01022,200
Stockholders� Equity
Common stock, $0.001 par value; 500,000,000 authorized as of each of June30, 2025 and 2024; 136,903,271 issued and 135,440,292 outstanding as of June 30, 2025 and 136,152,858 issued and 136,116,299 outstanding as of June30, 2024.137136
Treasury stock at cost, 1,462,979 and 36,559 shares as of June 30, 2025 and June 30, 2024, respectively(7,500)(179)
Additional paid-in capital343,378337,615
Retained deficit(101,047)(68,311)
Total InnovAge Holding Corp.234,968269,261
Noncontrolling interests2,9308,347
Total stockholders� equity237,898277,608
Total liabilities and stockholders� equity$526,851$547,661

Schedule 2

InnovAge
CONDENSED CONSOLIDATED STATEMENTS OFOPERATIONS
(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)

Three Months EndedYear Ended
June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Revenues
Capitation revenue$221,060$199,080$852,353$762,570
Other service revenue3573211,3461,285
Total revenues221,417199,401853,699763,855
Expenses
External provider costs108,169102,691431,152403,010
Cost of care, excluding depreciation and amortization71,96160,132268,908228,781
Sales and marketing7,1006,54128,21724,957
Corporate, general and administrative27,82329,591122,058111,337
Depreciation and amortization3,3945,32919,51018,950
Impairments and loss on assets held for sale5,12013,615
Total expenses223,567204,284883,460787,035
Operating Loss(2,150)(4,883)(29,761)(23,180)
Other Income (Expense)
Interest expense, net(893)(1,404)(4,612)(4,023)
(Loss) gain on cost and equity method investments(1,409)4,842(1,393)2,842
Other income, net2504991,7392,542
Total other (expense) income(2,052)3,937(4,266)1,361
Loss Before Income Taxes(4,202)(946)(34,027)(21,819)
Provision for Income Taxes8071,3081,3161,402
Net Loss(5,009)(2,254)(35,343)(23,221)
Less: net loss attributable to noncontrolling interests(4,224)(554)(5,030)(1,883)
Net Loss Attributable to InnovAge Holding Corp.$(785)$(1,700)$(30,313)$(21,338)
Weighted-average number of common shares outstanding - basic135,133,574136,023,975135,387,555135,902,214
Weighted-average number of common shares outstanding - diluted135,133,574136,023,975135,387,555135,902,214
Net loss per share - basic$(0.01)$(0.01)$(0.22)$(0.16)
Net loss per share - diluted$(0.01)$(0.01)$(0.22)$(0.16)

Schedule 3

InnovAge
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)

Year Ended June 30,
20252024
Operating Activities
Net loss$(35,343)$(23,221)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Loss on disposal of assets50878
Provision for uncollectible accounts5247,010
Depreciation and amortization19,51018,950
Operating lease rentals6,3615,339
Loss (gain) on cost and equity method investments1,393(2,842)
Impairments and loss on assets held for sale13,615
Amortization of deferred financing costs429429
Stock-based compensation7,6196,832
Deferred income taxes1,3011,224
Other1,7141,449
Changes in operating assets and liabilities, net of acquisitions
Accounts receivable, net11,210(30,333)
Prepaid expenses(4,041)(703)
Income tax receivable14(3,062)
Deposits and other(6,419)(2,829)
Accounts payable and accrued expenses20,4311,370
Reported and estimated claims3,56712,294
Due to Medicaid and Medicare(814)6,054
Income taxes payable(1,212)
Operating lease liabilities(8,713)(5,610)
Deferred revenue(28,115)
Net cash provided by (used in) operating activities32,866(36,898)
Investing Activities
Purchases of property and equipment(6,263)(7,914)
Purchases of short-term investments(2,065)(2,385)
Proceeds from sale of short-term investments6,3003,000
Proceeds from dissolution of equity method investments1,2524,842
Acquisition of business(4,774)(23,916)
Net cash used in investing activities$(5,550)$(26,373)
Financing Activities
Payments for finance lease obligations(6,107)(4,637)
Principal payments on long-term debt(3,799)(3,795)
Repurchase of equity securities(7,321)(179)
Contribution from joint venture partner2,900
Taxes paid related to net settlements of stock-based compensation awards(1,855)(1,323)
Net cash used in financing activities(19,082)(7,034)
Net change in cash, cash equivalents and restricted cash including cash of $1.05 million reclassified to assets held for sale8,234(70,305)
Less: change in cash and restricted cash reclassified to assets held for sale(1,054)
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS & RESTRICTED CASH7,180(70,305)
CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD56,960127,265
CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD$64,140$56,960
Supplemental Cash Flows Information
Interest paid$4,348$4,063
Income taxes paid$1$4,452
Property and equipment included in accounts payable$1,734$181
Property and equipment purchased under capital leases$1,533$4,142

Schedule 4

InnovAge
RECONCILIATION OF GAAP AND NON-GAAP MEASURES
(IN THOUSANDS) (UNAUDITED)

Adjusted EBITDA

Three Months EndedYear Ended
June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Net Loss$(5,009)$(2,254)$(35,343)$(23,221)
Interest expense, net8931,4044,6124,023
Other investment income(a)(497)(598)(2,247)(2,385)
Depreciation and amortization3,3945,32919,51018,950
Provision for income tax8071,3081,3161,402
Stock-based compensation1,5501,6927,6196,832
Litigation costs and settlement(b)1,6262,076
19,3674,878
M&A diligence, transaction and integration(c)(222)394
1,360778
Business optimization(d)2,195727
3,0404,399
EMR implementation(e)1
3,660
Loss (gain) on cost and equity method investments(f)1,393(4,842)$1,393$(2,842)
Asset impairments and loss on assets held for sale(g)4,97613,615
Loss on sale of assets(h)220220
Adjusted EBITDA$11,326$5,237
$34,462$16,474
Net loss margin(2.3)%(1.1)%(4.1)%(3.0)%
Adjusted EBITDA margin5.1%2.6%4.0%2.2%


(a)Reflects investment income related to short term investments included in our consolidated statements of operations.
(b)Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center, civil investigative demands, and arbitration with our former pharmacy provider. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy. For the year ended June 30, 2025, includes $10.1 million accrued in connection with the potential settlement of the previously disclosed stockholder class action.
(c)Reflects charges related to M&A transaction and integrations.
(d)Reflects charges related to business optimization initiatives. Such charges related to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations. For the year ended June30, 2025 this includes (i) $2.5 million of costs associated with organizational restructure and executive severance, and (ii) $0.5 million related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the year ended June 30, 2024, this includes (i) $3.1 million of costs associated with third party consultants to implement core provider initiatives, assess our risk-bearing capabilities, and strengthen our enterprise capabilities, (ii) $0.3 million of costs associated with organizational restructure, and (iii) $0.9 million related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the three months ended June 30, 2025, this includes $2.1 million of costs associated with third party consultants to implement core provider initiatives, assess our risk-bearing capabilities, and strengthen our enterprise capabilities. For the three months ended June 30, 2024, costs include (i) $0.5 million in third party consultants to implement our core provider initiatives, assess our risk-bearing payor capabilities, and strengthen our enterprise capabilities and (ii) $0.2 million in fees associated with the Pinewood Lodge, LLLP (PWD�) dissolution.
(e)Reflects non-recurring expenses relating to the implementation of a new EMR vendor.
(f)For the year ended June 30, 2025, reflects $2.6 million impairment loss for the investment in DispatchHealth Holdings Inc. partially offset by $1.3 million net benefit associated with the dissolution of the PWD partnership. For the year ended June 30, 2024, reflects $4.8 million net benefit associated with the dissolution of the PWD partnership partially offset by $2.0 million impairment in Jetdoc investment.
(g)Reflects (i) impairment charges related to ROU asset and construction in progress related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing, (ii) loss on assets held for sale, and (iii) loss on settlement of lease liability in Louisville, Kentucky.
(h)Reflects loss on sale of center equipment that was originally purchased for the center in Louisville, Kentucky.


Three Months Ended
March 31, 2025
Net Loss$(11,133)
Interest expense, net1,160
Other investment income(a)(503)
Depreciation and amortization5,386
Provision for income tax72
Stock-based compensation2,035
Litigation costs and settlement(b)13,277
M&A diligence, transaction and integration(c)202
Business optimization(d)152
EMR implementation(e)
Loss on cost and equity method investments(f)
Asset impairments and loss on assets held for sale(g)144
Adjusted EBITDA$10,792
Net loss margin(5.8)%
Adjusted EBITDA margin5.6%


(a)Reflects investment income related to short term investments included in our consolidated statement of operations.
(b)Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center, and civil investigative demands. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy. For the three months ended March 31, 2025, includes $10.7 million accrued in connection with the potential settlement of the previously disclosed stockholder class action.
(c)Reflects charges related to M&A transaction and integrations.
(d)Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations. For the three months ended March 31, 2025, this primarily includes costs related to other non-recurring projects aimed at reducing costs and improving efficiencies.
(e)Reflects non-recurring expenses relating to the implementation of a new EMR vendor.
(f)Reflects (i) impairment charges related to ROU asset and construction in progress related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing and (ii) loss on sale of center equipment that was originally purchased for the center in Louisville, Kentucky.
(g)Reflects impairment charges related to our minority equity interest in Jetdoc, Inc.

Center-Level Contribution Margin

Year Ended June 30, 2025Year Ended June 30, 2024
in thousandsPACEAll other(1)TotalsPACEAll other(1)Totals
Capitation revenue$852,353$$852,353$762,570$$762,570
Other service revenue3569901,3463109751,285
Total revenues852,709990853,699762,880975763,855
External provider costs431,152431,152403,010403,010
Cost of care, excluding depreciation and amortization268,338570268,908228,203578228,781
Center-Level Contribution Margin153,219420153,639131,667397132,064
Sales and marketing28,21724,957
Corporate, general and administrative122,058111,337
Depreciation and amortization19,51018,950
Impairments and loss on assets held for sale13,615
Operating loss(29,761)(23,180)
Other income(4,266)1,361
Loss Before Income Taxes$(34,027)$(21,819)
Loss Before Income Taxes as a % of revenue(4.0)%(2.9)%
Center- Level Contribution Margin as a % of revenue18.0%17.3%


Three Months Ended June 30, 2025Three Months Ended June 30, 2024
in thousandsPACEAll other(1)TotalsPACEAll other(1)Totals
Capitation revenue$221,060$$221,060$199,080$$199,080
Other service revenue10425335778243321
Total revenues221,164253221,417199,158243199,401
External provider costs108,169108,169102,691102,691
Cost of care, excluding depreciation and amortization71,81614571,96159,97615660,132
Center-Level Contribution Margin41,17910841,28736,4918736,578
Sales and marketing7,1006,541
Corporate, general and administrative27,82329,591
Depreciation and amortization3,3945,329
Impairments and loss on assets held for sale5,120
Operating loss(2,150)(4,883)
Other income(2,052)3,937
Loss Before Income Taxes$(4,202)$(946)
Loss Before Income Taxes as a % of revenue(1.9)%(0.5)%
Center- Level Contribution Margin as a % of revenue18.6%18.3%

Center-Level Contribution Margin

Three Months Ended March 31, 2025
(In thousands)PACEAll other(1)Totals
Capitation revenue$217,819$$217,819
Other service revenue79244323
Total revenues217,898244218,142
External provider costs107,896107,896
Cost of care, excluding depreciation and amortization69,37212769,499
Center-Level Contribution Margin40,63011740,747
Sales and marketing6,922
Corporate, general and administrative38,597
Depreciation and amortization5,386
Impairments and loss on assets held for sale
Operating Loss(10,158)
Other income(903)
Loss Before Income Taxes(11,061)
Loss Before Income Taxes as a % of revenue(5.1)%
Center- Level Contribution Margin as a % of revenue18.7%


(1)Center-level Contribution Margin from a segment below the quantitative thresholds was attributable to the Senior Housing operating segment of the Company as of June 30, 2025. This segment has never met any of the quantitative thresholds for determining reportable segments.

This press release was published by a CLEAR® Verified individual.


FAQ

What were InnovAge's (INNV) key financial results for fiscal year 2025?

InnovAge reported revenue of $853.7 million (up 11.8%), net loss of $35.3 million, and Adjusted EBITDA of $34.5 million. The company served 7,740 participants across 20 centers in six states.

What is InnovAge's (INNV) financial guidance for fiscal year 2026?

InnovAge expects FY2026 revenue between $900-950 million, census of 7,900-8,100 participants, and Adjusted EBITDA of $56-65 million.

How did InnovAge's (INNV) participant census perform in fiscal 2025?

InnovAge's census grew to 7,740 participants in fiscal 2025, up from 7,020 participants in 2024, representing a 10.3% increase.

What was InnovAge's (INNV) Adjusted EBITDA margin in fiscal 2025?

InnovAge's Adjusted EBITDA margin was 4.0% in fiscal 2025, an improvement of 1.9 percentage points from 2.2% in fiscal 2024.

How did InnovAge's (INNV) Center-level Contribution Margin perform in 2025?

Center-level Contribution Margin increased 16.3% to $153.6 million, with margin as percent of revenue improving to 18.0% from 17.3% in 2024.
Innovage Holding Corp.

NASDAQ:INNV

INNV Rankings

INNV Latest News

INNV Latest SEC Filings

INNV Stock Data

544.10M
19.17M
85.67%
12.14%
0.22%
Medical Care Facilities
Services-health Services
United States
DENVER